Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 14;9(1):176-179.
doi: 10.1182/bloodadvances.2024014097.

MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma

Lucia Y Chen  1 , Santiago Thibaud  2 , Saoirse Bodnar  2 , Ajai Chari  3 , Joshua Richter  2 , Hearn Jay Cho  2 , Larysa J Sanchez  2 , Cesar Rodriguez  2 , Adriana C Rossi  2 , Shambavi Richard  2 , Samir Parekh  2 , Sundar Jagannath  2
Affiliations

MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma

Lucia Y Chen et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure:A.C. reports research support from Janssen and consulting for AbbVie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, FORUS, Genentech Roche, GlaxoSmithKline, Janssen, Karyopharm, Millennium Takeda, and Sanofi Genzyme. H.J.C. reports employment with the Multiple Myeloma Research Foundation and research support from GenentechRoche, Bristol Myers Squibb, and Takeda, unrelated to this project. L.J.S. reports consulting and advisory board roles for Janssen. C.R. reports research support from Amgen, Janssen, Bristol Myers Squibb, and Teneobio; consulting for Amgen, Janssen, Bristol Myers Squibb, Karyopharm, Sanofi, and Artiva; speakers bureau roles for Bristol Myers Squibb; and scientific advisory board roles for Bristol Myers Squibb, Janssen, Sanofi, and Artiva. A.C.R. reports consulting for Johnson & Johnson, Bristol Myers Squibb, Karyopharm, Adaptive, and Sanofi. S.R. reports honoraria received from Janssen and Bristol Myers Squibb; steering committee roles with Gracell Therapeutics and Bristol Myers Squibb; research support from Janssen, Bristol Myers Squibb, C4 Therapeutics, Gracell Therapeutics, and Heidelberg Pharma; and advisory board roles for Genentech and Janssen. S.P. reports research support from Bristol Myers Squibb, Grail, and Caribou; and advisory board roles for Grail. S.J. reports consulting for Janssen, Bristol Myers Squibb, Caribou, Legend Biotech, Regeneron, Takeda, Sanofi, and Poseida; advisory board and data monitoring committee roles for Genmab, Sanofi, and Janssen; and advisory board roles for GlaxoSmithKline and Bristol Myers Squibb. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Disposition of patients undergoing serial testing for CR, MRD status in the bone marrow and imaging and the outcome of patients in CR with imaging and MRD negative ≥5 years. (A) Workflow demonstrating systematic approach to definition of patients at our center with ≥3 consecutive MRD-negative years and concurrently in CR and imaging negative. (B) PFS of patients with MM at Icahn School of Medicine at Mount Sinai in CR with imaging and MRD negative ≥5 years from the start of their latest line of therapy. (C) Landmark analysis of PFS from the start of MRD negativity, according to different MRD-negative durations.
See this image and copyright information in PMC

References

    1. Paiva B, Gutiérrez NC, Rosiñol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687–691. - PubMed
    1. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma. JAMA Oncol. 2017;3(1):28–35. - PMC - PubMed
    1. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. - PubMed
    1. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540–2547. - PubMed
    1. Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–2464. - PMC - PubMed